文献速递肺栓塞与肺血管病

新发肺动脉高压患者的治疗模式:肺动脉高压协会登记处的真实世界数据

Treatment Patterns in Patients With Incident Pulmonary Hypertension: Real-World Data From the Pulmonary Hypertension Association Registry.
PubMed 文献 · Chest · 2025-12-08

该研究基于肺动脉高压协会登记处(PHAR)2015年9月30日至2024年2月14日前瞻性收集的1019例新发肺动脉高压(PAH)患者,评估指南推荐的风险导向治疗模式。结果显示初始单药、双药和三药治疗分别占33.8%、54.7%和11.6%,各风险分层中均有患者未按指南推荐强度治疗,提示真实世界中PAH治疗利用不足。

要点

  • 新发PAH初始治疗以双药为主(54.7%),单药33.8%,三药仅11.6%。
  • 各治疗组中均有低危患者接受单药、高危患者未接受三药治疗。
  • 全因死亡率在低危患者中最低、高危患者中最高,跨治疗组一致。

核心结论

  • 真实世界中新发PAH患者的指南推荐治疗利用不足。
  • 初始单药、双药和三药治疗在各风险分层中均有分布,未完全遵循风险导向策略。

研究设计与样本

  • 前瞻性队列分析,纳入PHAR登记处2015年9月30日至2024年2月14日经右心导管确诊的新发PAH患者,共1019例。
  • 主要目标是评估指南推荐的风险导向治疗方式及其真实世界影响,比较不同风险组及不同初始治疗方案的全程死亡率。

主要发现

  • 1019例患者中初始单药344例(33.8%)、双药557例(54.7%)、三药118例(11.6%)。
  • 在323例有完整风险分层的初始单药患者中,低危25.1%、中危31.3%、高危43.7%(REVEAL Lite 2评分)。
  • 在540例初始双药患者中,低危35.7%、中危26.5%、高危37.8%;113例初始三药患者中,低危31.9%、中危28.3%、高危39.8%。
  • 全因死亡率在基线低危患者中最低、高危患者中最高,且在全队列及初始单药、双药、三药治疗组中均一致。

关键数值与推荐

  • 当前证据支持低危和中危PAH患者初始使用内皮素受体拮抗剂联合磷酸二酯酶5抑制剂,高危患者加用胃肠外前列环素的三联治疗。

临床怎么用

  • 临床应依据风险分层为低危和中危患者启动双药联合治疗,为高危患者考虑包含胃肠外前列环素的三药治疗。
  • 真实世界中高危患者接受单药治疗的比例较高,需加强指南推荐的治疗强度以改善预后。

局限性

  • 仅部分患者(323例单药、540例双药、113例三药)具备完整风险分层数据,可能存在选择偏倚。
  • 观察性登记数据无法完全排除混杂因素对死亡率比较的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current evidence supports risk-based treatment for pulmonary arterial hypertension (PAH) with an endothelin receptor antagonist and phosphodiesterase type 5 inhibitor as initial therapy for patients with low- and intermediate-risk PAH, and triple therapy with the addition of a parenteral prostacyclin for patients with high-risk PAH. RESEARCH QUESTION: What are the current treatment patterns for patients with newly diagnosed PAH in the Pulmonary Hypertension Association Registry (PHAR)? STUDY DESIGN AND METHODS: This analysis was performed in a prospectively collected cohort of patients with incident PAH diagnosed by right heart catheterization and enrolled in the PHAR between September 30, 2015, and February 14, 2024. The primary objective was to assess the guideline-recommended risk-based treatment approaches and their impact in the real world. All-cause mortality was compared across risk groups and between patients receiving monotherapy, dual therapy, and triple therapy for PAH across risk strata. RESULTS: There were 1,019 patients with incident PAH in the PHAR who received either initial monotherapy (n = 344, 33.8%), dual therapy (n = 557, 54.7%), or triple therapy (n = 118, 11.6%). Of 323 patients with complete data for risk classification who received initial monotherapy, 25.1% were low risk, 31.3% were intermediate risk, and 43.7% were high risk by Registry to Evaluate Early and Long-term PAH Disease Management Lite 2 risk score. For the 540 patients treated with initial dual therapy, 35.7% were low risk, 26.5% were intermediate risk, and 37.8% were high risk. Finally, among the 113 patients who received initial triple therapy, 31.9% were low risk, 28.3% were intermediate risk, and 39.8% were high risk. All-cause mortality was lowest for patients with low-risk PAH at baseline and highest for those with high-risk PAH at baseline across the entire cohort and for patients treated with initial monotherapy, dual therapy, or triple therapy. INTERPRETATION: This analysis highlights the underutilization of PAH therapies for patients with newly diagnosed PAH in this real-world patient population.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Khan SL, Paoli CJ, Kime N, et al. Treatment Patterns in Patients With Incident Pulmonary Hypertension: Real-World Data From the Pulmonary Hypertension Association Registry. Chest. 2025. PMID: 41371490. doi:10.1016/j.chest.2025.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。